Status:
RECRUITING
Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Conditions:
Migraine Disorders
Eligibility:
All Genders
18+ years
Brief Summary
To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.
Eligibility Criteria
Inclusion
- \-
Exclusion
- patients with a known hypersensitivity to components of AJOVY
Key Trial Info
Start Date :
April 20 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 22 2029
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05342493
Start Date
April 20 2022
End Date
June 22 2029
Last Update
March 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pharmacovigilance Department
Osaka, Japan, 540-0021